| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5583919 | Seminars in Arthritis and Rheumatism | 2017 | 10 Pages |
Abstract
Taking in account the paucity of controlled trials, second-line biologic therapy may be reasonably optimized in patients with RA, SpA, and PsA.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Fabrizio MD, Laura MD, Carlotta MD, Emanuele MD, Olga MD, Ennio MD, Andrea MD, Maurizio MD, Francesca Li MD, Serena MD, Rosario MD, Marta MD, Delia MD,